Adial Pharmaceuticals Faces Delisting Notice

Ticker: ADIL · Form: 8-K · Filed: May 30, 2025 · CIK: 1513525

Adial Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyAdial Pharmaceuticals, Inc. (ADIL)
Form Type8-K
Filed DateMay 30, 2025
Risk Levelhigh
Sentimentbearish

Sentiment: bearish

Topics: delisting, listing-standards, regulatory

Related Tickers: ADIL

TL;DR

ADIL got a delisting warning, might be kicked off the exchange.

AI Summary

Adial Pharmaceuticals, Inc. filed an 8-K on May 30, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's principal executive offices are located at 4870 Sadler Road, Ste 300, Glen Allen, VA 23060. The filing date indicates the earliest event reported was May 23, 2025.

Why It Matters

This filing signals potential delisting from a stock exchange, which could significantly impact the company's liquidity and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting directly threatens the company's ability to trade on a major exchange, posing a significant risk to its operations and stock value.

Key Players & Entities

  • Adial Pharmaceuticals, Inc. (company) — Registrant
  • May 23, 2025 (date) — Earliest event reported
  • May 30, 2025 (date) — Filing date
  • 4870 Sadler Road, Ste 300 Glen Allen, VA 23060 (address) — Principal executive offices

FAQ

What specific listing rule or standard has Adial Pharmaceuticals, Inc. failed to satisfy?

The filing does not specify the exact rule or standard that Adial Pharmaceuticals, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.

What is the earliest event date reported in this 8-K filing?

The earliest event reported in this 8-K filing is May 23, 2025.

When was this 8-K filing submitted to the SEC?

This 8-K filing was submitted to the SEC on May 30, 2025.

Where are Adial Pharmaceuticals, Inc.'s principal executive offices located?

Adial Pharmaceuticals, Inc.'s principal executive offices are located at 4870 Sadler Road, Ste 300, Glen Allen, VA 23060.

What is the Commission File Number for Adial Pharmaceuticals, Inc.?

The Commission File Number for Adial Pharmaceuticals, Inc. is 001-38323.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 30, 2025 regarding ADIAL PHARMACEUTICALS, INC. (ADIL).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.